


The MorphoSys Share

During the 2011 fiscal year, MorphoSys's stock price showed a 5 % decrease, while the German TecDAX index decreased by 19 %. The NASDAQ biotechnology index rose by 11 % in 2011.




KEY DATA FOR THE MORPHOSYS SHARE (as of December 31 of each year)

in € million (if not stated otherwise)	2011	2010	2009	2008	2007
Total Stockholders' Equity	197.1	185.9	173.9	162.0	145.5
Number of Shares Issued (Total)	23,112,167	22,890,252	22,660,557	22,478,787	22,160,259
Market Capitalization	405	424	386	421	357
Closing Price (Xetra) in €	17.53	18.53	17.04	18.75	16.10
Average Daily Trading Volume	1.8	1.1	1.3	1.9	2.5

SHAREHOLDER STRUCTURE


Shareholdings by Investor Type (in %)

Institutional Investors	46.0
Retail Investors	22.0
Novartis	6.4
Management and Supervisory Boards	1.9
Treasury Stock	0.7
Unidentified Investors	23.0



Geographic Split of Institutional Holdings (in %)

UK	11
Scandinavia	10
Switzerland	7
Benelux	6
Germany	4
France	4
Other Countries	2
USA	57



The economic turbulence on the European market put pressure on the share price development of most companies. The performance of MorphoSys's stock was also influenced by the extremely volatile market situation.

LIQUIDITY AND INDEX MEMBERSHIP

The average daily trading volume of MorphoSys's stock increased to €1.8 million per day, compared to an average trading volume of €1.1 million per day in the previous year. MorphoSys further strengthened its position in the **TecDAX** index, which includes the 30 largest technology stocks on the Frankfurt Stock Exchange. At the end of 2011, the Company was able to improve

its position based on **market capitalization** to 14 th place (year-end 2010: rank 16) and its position based on trading volume to 20 th place (year-end 2010: rank 23).

STOCKHOLDER BASE

The free float according to Deutsche Börse AG, which is generally taken into account in the weighting of MorphoSys's stock in stock indices, was 88% of the share capital at year-end 2011.

Please visit our [website](#) for the most recent information on investor relations.



SEE GLOSSARY
SEE PAGE 152



SEE GLOSSARY
SEE PAGE 152



ADDITIONAL INFORMATION
WWW.MORPHOSYS.COM